Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin for Neonatal Encephalopathy in LMICs
NCT05395195Phase 3Recruiting
- Sponsor
- Imperial College London
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of erythropoietin in neonatal encephalopathy (NE) (2 arms), sponsored by Imperial College London. Primary endpoint: Number of babies who die or survive with moderate or severe disability. Started Dec 2022; status: recruiting.
02
Drugs
erythropoietin
03
Conditions
neonatal encephalopathy (NE)
Beyond the preview
Go deeper on NCT05395195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395195.